Onglyza expands European licence

pharmafile | March 4, 2011 | News story | Sales and Marketing |  AZ, AstraZeneca, BMS, Bristol-Myers Squibb, Onglyza, diabetes, renal impairment, saxagliptin, type II diabetes 

European regulators have approved a licence extension for diabetes treatment Onglyza, making it the first drug in its class that can also treat moderate or severe renal impairment.

It is estimated that more than 25% of patients with type II diabetes have moderate or severe renal impairment and doctors will now have the option of prescribing Onglyza, but only at half its normal 5mg dose.

They will also need to assess their patients’ renal function prior to treatment commencing and, in keeping with routine care, regularly monitor them after treatment begins.

The companies further note that “as experience in patients with severe renal impairment is very limited, [Onglyza] should be used with caution in this population and is not recommended for patients with end-stage renal failure”.

Advertisement

Patients with mild renal impairment will be able to take a full 5mg dose of Onglyza (saxagliptin).

The drug is co-promoted by AstraZeneca and Bristol-Myers Squibb and currently indicated to help type II diabetics keep their sugar levels low.

Ben Adams

Related Content

AstraZeneca’s Trixeo approved in EU for asthma

AstraZeneca’s Trixeo Aerosphere (budesonide/glycopyrronium/formoterol fumarate dihydrate) has been approved in the European Union as a …

Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial

Boehringer Ingelheim’s investigational survodutide produced weight loss of up to 13.1% after 76 weeks in …

Study to examine ways of improving diabetes care for younger adults

Researchers at Northumbria University are leading a ÂŁ1.3m study aimed at helping GP practices improve …

The Gateway to Local Adoption Series

Latest content